^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
Excerpt:
The median age was 65 years (range: 24-93); 87% of patients had Eastern Cooperative Oncology Group performance status 0-1, 56% of patients had KRAS, 7% had NRAS and 4% had BRAF mutations. The initial regorafenib dose was 160 mg/day in 57% of patients….Median OS was 7.7 months (95% confidence interval [CI]: 7.2-8.3), and median progression-free survival (PFS) was 2.9 months (95% CI: 2.8-3.0).
DOI:
10.1016/j.ejca.2019.09.015
Trial ID:
Source:
Title:
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
Excerpt:
...Proportion of patients with a DoT to Stivarga of more than 4 months versus total study sample`ECOG: Eastern Cooperative Oncology Group`ECOG performance status (0, 1)`Rectum, Left-sided colon, Right-sided colon, Colon and rectum, Transverse, Unknown (in colon)`Primary site of disease`Tumor resection (yes, no, unknown)`Lung, Liver, Bone, Extraregional nodes, Peritoneum, Multiple, Unknown`Specific site of metastasis`KRAS mutation (yes, no, unknown)`RAS mutation (yes, no, unknown)`BRAF mutation (yes, no, unknown)...
Trial ID:
Source:
Title:
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
Excerpt:
...Percentage of patients with mutated BRAF status at index`Percentage of patients with mutated KRAS status at index.`...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.
Published date:
05/25/2023
Excerpt:
11 (68.7%) patients were enrolled within 18 months from diagnosis of mCRC. RAS and BRAF mutation were detected in 8 (50.0%) and 1 (6.3%) patients. Among 13 evaluable patients, 11 achieved SD and 2 had PD, with the DCR of 84.6% (95% CI: 54.6%-98.1%). The median PFS was 4.9 months (95% CI: 2.8-7.0)...Regorafenib plus biweekly TAS-102 exhibited promising benefits in terms of DCR and PFS, and could be a novel treatment option for patients with refractory mCRC. The adverse events were generally tolerable and manageable.
Secondary therapy:
trifluridine/tipiracil
DOI:
10.1200/JCO.2023.41.16_suppl.e15567
Source:
Title:
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review
Published date:
08/08/2020
Excerpt:
We identified 12 articles involving eight RCTs studies analyzing 6805 patients. The studies compared bevacizumab (3), regorafenib (1), panitumumab (2), cetuximab (3), ramucirumab (1), conatumumab (1), ganitumab (1), and aflibercept (1) against chemotherapy alone as comparator....Regorafenib combined with chemotherapy might be a potential alternative to conventional therapeutic options in second-line treatment of patients with metastatic colorectal cancer and could be considered as the best option for treating patients with KRAS and BRAF mutated mCRC....
Secondary therapy:
Chemotherapy
DOI:
10.1007/s12325-020-01447-2
Source:
Title:
Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
Excerpt:
Compared with control cells, proliferation and migration of all the tumor cell lines were inhibited by clinically effective concentrations of regorafenib (5–8 μM), irrespective of their KRAS and BRAF mutation status (Fig. 1).
DOI:
10.1111/cas.12907
